trial

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

NCTId NCT05193578
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 154 (actual)
Sponsored by Jan Frystyk
Primary completion 2024-03-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
154 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-01-01
Primary completion
2024-03-18
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Semaglutide, 1.34 mg/mL

Sponsors

Jan FrystykLead Sponsor
Region ZealandCollaborator
Region of Southern DenmarkCollaborator
Steno Diabetes Center SjaellandCollaborator
Steno Diabetes Center OdenseCollaborator

Investigators

1
Jan Frystyk, ProfessorPrincipal Investigator

Sites

1 total
Odense, Denmark

Linked catalysts

1
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Predi — primary completion2024-03-18

Facts & assertions

4 sourced
Enrollment
154
Phase
PHASE2
Primary Completion Date
2024-03-18
Status
COMPLETED
relationships
The graph out of here
drug
Semaglutide, 1.34 mg/mL
drug
lead_sponsor
Jan Frystyk
company
collaborator
Region Zealand
company
Region of Southern Denmark
company
indication
Overweight
indication
Prediabetic State
indication
Metabolic Syndrome
indication
investigator
Jan Frystyk, Professor
person